N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of nanoparticle technology Nuvec - Notes SRI International has successfully completed the chemistry work and shown that a fox three molecular guidance system can be added to Nuvec without altering its loading capability. Chief Executive Nigel Theobald says: ‘This is an exciting development for us as it clearly shows that Nuvec is capable of targeting specific cells via the addition of a relevant ligand, something the industry is actively looking for. We will now start working on a combined marketing pitch deck allowing SRI and N4 Pharma to present this data and its implications to major pharma and biotech players that need a targeting delivery system for their nucleic acid programs.’ N4 Pharma says the next step is to show that small interfering RNA still retains its functionality in the target cell.
Current stock price: 0.59 pence per share, up 8.0% late Tuesday morning in London
12-month change: down 60%
Copyright 2024 Alliance News Ltd. All Rights Reserved.
